Abstract
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment of primary and secondary lung tumours is appraised, and key ongoing trials are identified.
| Original language | English |
|---|---|
| Pages (from-to) | 351-360 |
| Number of pages | 10 |
| Journal | Cancer Imaging |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 28 Sept 2012 |
Keywords
- Stereotactic ablative body radiotherapy
- lung
- cancer
- radiosurgery
- RADIATION-THERAPY SBRT
- PROSPECTIVE PHASE-II
- LONG-TERM
- COMPUTED-TOMOGRAPHY
- PULMONARY-FUNCTION
- CANCER PATIENTS
- I/II TRIAL
- STAGE
- METASTASES
- SURVIVAL
